These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 12529668

  • 1. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 2. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 3. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 4. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep 18; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.
    Leukemia; 2002 Oct 18; 16(10):2027-36. PubMed ID: 12357354
    [Abstract] [Full Text] [Related]

  • 6. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 18; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 7. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 18; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 8. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 9. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.
    Blood; 2000 Dec 01; 96(12):3907-14. PubMed ID: 11090077
    [Abstract] [Full Text] [Related]

  • 10. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
    Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M.
    Leukemia; 2003 Jan 01; 17(1):114-9. PubMed ID: 12529667
    [Abstract] [Full Text] [Related]

  • 11. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Wang LY, Chang WH.
    Leukemia; 2003 May 01; 17(5):883-6. PubMed ID: 12750701
    [Abstract] [Full Text] [Related]

  • 12. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT, Levis M, Small D.
    Br J Haematol; 2006 Sep 01; 134(5):500-9. PubMed ID: 16869825
    [Abstract] [Full Text] [Related]

  • 13. Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5.
    Takahashi S, Harigae H, Kaku M, Sasaki T, Licht JD.
    Biochem Biophys Res Commun; 2004 Mar 26; 316(1):85-92. PubMed ID: 15003515
    [Abstract] [Full Text] [Related]

  • 14. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ, Xue J, Corey SJ.
    Exp Hematol; 2005 Apr 26; 33(4):469-79. PubMed ID: 15781338
    [Abstract] [Full Text] [Related]

  • 15. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A, Johansson B, Lassen C, Mitelman F, Billström R, Fioretos T.
    Eur J Haematol; 2004 May 26; 72(5):307-13. PubMed ID: 15059064
    [Abstract] [Full Text] [Related]

  • 16. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H.
    Leukemia; 2008 Jan 26; 22(1):78-86. PubMed ID: 17943165
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.
    Oncogene; 2002 Apr 11; 21(16):2555-63. PubMed ID: 11971190
    [Abstract] [Full Text] [Related]

  • 18. FLT3 mutations in myeloid sarcoma.
    Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper L, Long P, Allan RH, Borowitz MJ, Berg KD, Murphy KM.
    Br J Haematol; 2004 Sep 11; 126(6):785-91. PubMed ID: 15352981
    [Abstract] [Full Text] [Related]

  • 19. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
    Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA.
    Cancer Res; 2001 Oct 01; 61(19):7233-9. PubMed ID: 11585760
    [Abstract] [Full Text] [Related]

  • 20. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.
    Blood; 2005 Jul 01; 106(1):265-73. PubMed ID: 15769897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.